blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2511281

EP2511281 - ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES AND MEDICINE USES THEREOF [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  10.07.2015
Database last updated on 31.08.2024
Most recent event   Tooltip05.08.2015New entry: Additional fee for renewal fee: despatch of communication + time limit 
Applicant(s)For all designated states
Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China
No. 27 Taiping Road
Haidian District, Beijing 100850 / CN
[2012/42]
Inventor(s)01 / ZHONG, Bohua
No. 27 Taiping Road
Haidian District
Beijing 100850 / CN
02 / HE, Xinhua
No. 27 Taiping Road
Haidian District
Beijing 100850 / CN
03 / WANG, Yongguang
No. 27 Taiping Road
Haidian District
Beijing 100850 / CN
04 / LIU, He
No. 27 Taiping Road
Haidian District
Beijing 100850 / CN
 [2012/42]
Representative(s)Weickmann & Weickmann PartmbB
Postfach 860 820
81635 München / DE
[N/P]
Former [2012/42]Böhm, Brigitte
Weickmann & Weickmann Patentanwälte Postfach 86 08 20
81635 München / DE
Application number, filing date10835359.021.06.2010
WO2010CN00902
Priority number, dateCN2009125216110.12.2009         Original published format: CN200910252161
[2012/42]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011069322
Date:16.06.2011
Language:ZH
[2011/24]
Type: A1 Application with search report 
No.:EP2511281
Date:17.10.2012
Language:EN
[2012/42]
Search report(s)International search report - published on:CN16.06.2011
(Supplementary) European search report - dispatched on:EP25.04.2013
ClassificationIPC:C07F9/40, A61K31/675, A61P31/12, C07F9/6561
[2013/22]
CPC:
C07F9/65616 (EP,US); A61P1/16 (EP); A61P31/12 (EP);
A61P31/20 (EP)
Former IPC [2012/42]C07F9/40, A61K31/675, A61P31/12
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/42]
TitleGerman:ACYCLISCHE NUCLEOSIDPHOSPHONATDERIVATE UND IHRE MEDIZINISCHE VERWENDUNG[2012/42]
English:ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES AND MEDICINE USES THEREOF[2012/42]
French:DÉRIVÉ DE NUCLÉOSIDE PHOSPHONATE ACYCLIQUE ET SON UTILISATION MÉDICALE[2012/42]
Entry into regional phase04.07.2012Translation filed 
04.07.2012National basic fee paid 
04.07.2012Search fee paid 
04.07.2012Designation fee(s) paid 
04.07.2012Examination fee paid 
Examination procedure04.07.2012Examination requested  [2012/42]
19.11.2013Amendment by applicant (claims and/or description)
30.06.2015Application withdrawn by applicant  [2015/33]
Fees paidRenewal fee
04.07.2012Renewal fee patent year 03
10.06.2013Renewal fee patent year 04
12.06.2014Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
30.06.201506   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XDY]EP0785208  (MITSUBISHI CHEM CORP [JP]) [XD] 1-12 * page 36 - page 37; compounds 1404, 1439 * * Markush formula of :;; claim 1 * * Pharmaceutical compositions :;; claim 17 * * Use of compounds as antiviral agent and for treatment of viral infections like hepatitis;; claims 18-19 * * Process of making the compounds of Markush formula I reacting 6-Chloro-9H-purin-2-amine (formula VI) with phosphonate (formula IV), then reacting with thiophenol derivative (formula VIII) to obtain a formula I' compound, which is then transesterified via hydrolysis to a phosphonic acid I'' (page 45) to a formula XIII compound according to claim 1, see:; page 43 - page 45 * [Y] 1-12;
 [Y]CN1827627  (BEIJING MEIBEITA PHARMACEUTICA [CN]) [Y] 1-12 * compound 2,2-dimethyl-propanoic acid 2,2-dimethyl-[[[2-[2-amino-6-[[4-(methylthio)phenyl]thio]-9H-purin-9-yl]ethoxy]methyl]phosphinylidene]bis(oxymethylene)-ester, with CAS registry number 909869-46-1. * * Pharmaceutical composition and use as antiviral agent:;; claim 10 *;
 [Y]CN101066981  (SHANGHAI INST OF MEDICINES CAS [CN]) [Y] 1-12 * page 5; compounds 21, 22 * * Use in treatment of viral infections, notably hepatitis and HIV;; claims 6-8 *
 [Y]  - JIN, YONGZENG ET AL, "Preparation of purine derivatives as antiviral agents for treatment of Hepatitis B", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 2006:940072, URL: STN, XP002695611 [Y] 1-12 * abstract *
International search[X]CN1164534  (MITSUBISHI CHEM CORP [JP]);
 [X]CN1827627  (BEIJING MEIBEITA PHARMACEUTICA [CN]);
 [A]CN1670024  (INST PHARM & TOXICOLOGY AMMS [CN])
by applicantEP0785208
    - CLARK CHAN ET AL., "Clinical Pharmacokinetics of Alamifovir and Its Metabolites", ANTIVICROB AGENTS CHEMOTHER, (2005), vol. 49, no. 5, pages 1813 - 1822
    - KAMIYA N ET AL., "Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B Virus", ANTIMICROB AGENTS CHEMOTHER, (2002), vol. 46, no. 9, doi:doi:10.1128/AAC.46.9.2872-2877.2002, page 2872, XP001153184

DOI:   http://dx.doi.org/10.1128/AAC.46.9.2872-2877.2002
    - SUZANE KIOKO ONO-NITA; ONO-NITA SK ET AL., "Novel Nucleoside analogue MCC-478 (LY582563)is effective against wild-type or lamivudine-resistant hepatitis B virus", ANTIMICROB AGENTS CHEMOTHER, (2002), vol. 46, doi:doi:10.1128/AAC.46.8.2602-2605.2002, pages 2602 - 2605, XP002245846

DOI:   http://dx.doi.org/10.1128/AAC.46.8.2602-2605.2002
    - CLARK CHAN ET AL., "Clinical Pharmaco-kinetics of Alamifovir and Its Metabolites", ANTIVICROB AGENTS CHEMOTHER, (2005), vol. 49, no. 5, pages 1813 - 1822
    - S. M. BERGE ET AL., "Pharmaceutical Salts", J. PHARM. SCI., (1977), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - PRESCOTT, ED., Methods in Cell Biology, ACADEMIC PRESS, (1976), vol. XIV, page 33
    - CLARK CHAN ET AL., CLINICAL PHARMACO-KINETICS OF ALAMIFOVIR AND ITS METABOLITES ANTIVICROB AGENTS CHEMOTHER, (2005), vol. 49, no. 5, pages 1813 - 1822
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.